Anemia News and Research

RSS

Anemia is a decrease in normal number of red blood cells (RBCs) or less than the normal quantity of hemoglobin in the blood. However, it can include decreased oxygen-binding ability of each hemoglobin molecule due to deformity or lack in numerical development as in some other types of hemoglobin deficiency. The three main classes of anemia include excessive blood loss (acutely such as a hemorrhage or chronically through low-volume loss), excessive blood cell destruction (hemolysis) or deficient red blood cell production (ineffective hematopoiesis). Anemia is the most common disorder of the blood. There are several kinds of anemia, produced by a variety of underlying causes. Anemia can be classified in a variety of ways, based on the morphology of RBCs, underlying etiologic mechanisms, and discernible clinical spectra, to mention a few.

New blood test could help identify babies at risk of sickle cell disease

A new blood test is being developed by researchers in Cambridge and Oxford, which, for the first time, could help identify babies at risk of a severe form of sickle cell disease, allowing immediate and more intensive treatment to be given, thanks to a grant from children's charity Action Medical Research.

7 Sep 2011

Tick-borne disease in US blood supply

A tick-borne infection known as Babesiosis, which can cause severe disease and even death, is becoming a growing threat to the U.S. blood supply, government researchers said on Monday.

6 Sep 2011

NOXXON to commence NOX-H94 Phase I trial in anemia of chronic disease

NOXXON Pharma today announced the initiation of a Phase I clinical trial for NOX-H94, the Company's third compound to enter the clinic. NOX-H94 is a Spiegelmer designed to treat anemia of chronic disease by targeting the peptide hormone hepcidin, the key regulator of iron metabolism.

6 Sep 2011

Positive topline data from 4SC's resminostat Phase II trial on Hodgkin's Lymphoma

4SC AG, a discovery and development company of targeted small molecule drugs for autoimmune diseases and cancer, today announced positive topline data from its Phase II SAPHIRE trial with resminostat, its oral pan HDAC inhibitor, in patients with relapsed/refractory Hodgkin's Lymphoma.

6 Sep 2011

Researchers discover new genetic defect that predisposes people to leukemia, myelodysplasia

A new genetic defect that predisposes people to acute myeloid leukemia and myelodysplasia has been discovered. The mutations were found in the GATA2 gene. Among its several regulatory roles, the gene acts as a master control during the transition of primitive blood-forming cells into white blood cells.

5 Sep 2011

Exercise triggers influential stem cells to become bone instead of fat

McMaster researchers have found one more reason to exercise: working out triggers influential stem cells to become bone instead of fat, improving overall health by boosting the body's capacity to make blood.

3 Sep 2011

Jefferson's two-step bone marrow transplant procedure holds promise for cancer patients

Half-matched bone marrow or stem cell transplants for blood cancer patients have typically been associated with disappointing clinical outcomes. However, a clinical trial conducted at the Kimmel Cancer Center at Jefferson testing its unique, two-step half-match procedure has produced some promising results: the probability of overall survival was 45 percent in all patients after three years and 75 percent in patients who were in remission at the time of the transplant.

2 Sep 2011

AmerisourceBergen completes acquisition of Premier Source

AmerisourceBergen Corporation today announced that it has completed the acquisition of Premier Source, a privately held company that provides consulting and reimbursement services to medical device, pharmaceutical, molecular diagnostic, and biotechnology manufacturers, as well as other health services companies.

2 Sep 2011

New clinical data on Bristol-Myers Squibb's NULOJIX to be presented at ESOT 2011 congress

Bristol-Myers Squibb Company today announced that new data on NULOJIX (belatacept) will be presented at the European Society for Organ Transplantation (ESOT) Congress on September 4 -7, 2011 in Glasgow, Scotland, United Kingdom.

2 Sep 2011

BancoVida, CBAI partner to offer umbilical cord blood collection services in Puerto Rico

Cord Blood America, Inc. announced today it has entered into an agreement with BancoVida to offer umbilical cord blood collection services in Puerto Rico and throughout the Caribbean.

29 Aug 2011

Vertex receives Health Canada approval for INCIVEK to treat hepatitis C

Vertex Pharmaceuticals Incorporated today announced that Health Canada has approved INCIVEK tablets for a broad group of people with genotype 1 chronic hepatitis C with compensated liver disease, including cirrhosis.

23 Aug 2011

FDA approves Seattle Genetics ADCETRIS drug to treat Hodgkin lymphoma, ALCL

Seattle Genetics, Inc. today announced that the U.S. Food and Drug Administration has granted accelerated approval of ADCETRISTM for two indications: (1) the treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates, and (2) the treatment of patients with systemic anaplastic large cell lymphoma after failure of at least one prior multi-agent chemotherapy regimen.

20 Aug 2011

Seattle Genetics receives FDA approval for Adcetris to treat Hodgkin lymphoma, ALCL

The U.S. Food and Drug Administration today approved Adcetris to treat Hodgkin lymphoma and a rare lymphoma known as systemic anaplastic large cell lymphoma.

20 Aug 2011

Premera, Cord Blood America partner to offer discount on stem cell collection services

Cord Blood America, Inc. today announced that it has entered into an agreement with Premera Blue Cross, a leading health plan provider with operations in Mountlake Terrace, Seattle and Spokane, Washington, and Anchorage, Alaska, and more than 1.4 million members, to store umbilical cord blood at a discounted rate consistent with other Blue Cross licensee contracts.

18 Aug 2011

Enrollment commences in Allos' FOLOTYN Phase 3 trial for peripheral T-cell lymphoma

Allos Therapeutics, Inc. today announced the enrollment of the first patient in a Phase 3 randomized clinical trial (PDX-017) evaluating FOLOTYN in patients with previously undiagnosed peripheral T-cell lymphoma.

18 Aug 2011

Medgenics second quarter net loss increases to $2.32 million

Medgenics, Inc., the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today reported financial results for the three and six months ended June 30, 2011.

12 Aug 2011

FDA assigns PDUFA action date for review of Affymax peginesatide NDA

Affymax, Inc. today announced that the U.S. Food and Drug Administration has assigned a Prescription Drug User Fee Act (PDUFA) action date of March 27, 2012 for the review of the investigational agent peginesatide New Drug Application.

12 Aug 2011

FDA acceptance of peginesatide NDA triggers $10M milestone payment to Affymax

Affymax, Inc. today announced that it has received a $10 million development milestone payment from Takeda Pharmaceutical Company as part of the companies' exclusive global agreement to develop and commercialize peginesatide (formerly known as Hematide™), Affymax's investigational drug for the treatment of anemia in chronic renal failure patients.

10 Aug 2011

Breastfeeding for up to one year after birth can reduce child mortality, UNICEF says

Breastfeeding from birth to six months or a year can reduce deaths among children under five by 13 percent, a fact UNICEF is highlighting during World Breastfeeding Week, which runs through August 7, the International Business Times reports.

4 Aug 2011

Acceleron, Celgene enter development collaboration for ACE-536 protein therapeutic to treat anemia

Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, and Celgene Corporation today announced that the companies have entered into a joint development and commercialization agreement for ACE-536 for the treatment of anemia.

3 Aug 2011

Anemia News and Research

Further Reading

New blood test could help identify babies at risk of sickle cell disease

Tick-borne disease in US blood supply

NOXXON to commence NOX-H94 Phase I trial in anemia of chronic disease

Positive topline data from 4SC's resminostat Phase II trial on Hodgkin's Lymphoma

Researchers discover new genetic defect that predisposes people to leukemia, myelodysplasia

Exercise triggers influential stem cells to become bone instead of fat

Jefferson's two-step bone marrow transplant procedure holds promise for cancer patients

AmerisourceBergen completes acquisition of Premier Source

New clinical data on Bristol-Myers Squibb's NULOJIX to be presented at ESOT 2011 congress

BancoVida, CBAI partner to offer umbilical cord blood collection services in Puerto Rico

Vertex receives Health Canada approval for INCIVEK to treat hepatitis C

FDA approves Seattle Genetics ADCETRIS drug to treat Hodgkin lymphoma, ALCL

Seattle Genetics receives FDA approval for Adcetris to treat Hodgkin lymphoma, ALCL

Premera, Cord Blood America partner to offer discount on stem cell collection services

Enrollment commences in Allos' FOLOTYN Phase 3 trial for peripheral T-cell lymphoma

Medgenics second quarter net loss increases to $2.32 million

FDA assigns PDUFA action date for review of Affymax peginesatide NDA

FDA acceptance of peginesatide NDA triggers $10M milestone payment to Affymax

Breastfeeding for up to one year after birth can reduce child mortality, UNICEF says

Acceleron, Celgene enter development collaboration for ACE-536 protein therapeutic to treat anemia

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News